New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
08:09 EDTACT, VRXActavis announces patent challenge settlement for Acanya
Actavis (ACT) announced that it has entered into an agreement with Valeant (VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya Gel, 1.2%/2.5%. Acanya Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant Actavis a license to market its generic Acanya Gel beginning in July 1, 2018 or earlier under certain circumstances. Other details of the settlement were not disclosed. For the 12 months ending February 28, Acanyaź had total U.S. sales of approximately $121M, according to IMS Health data.
News For ACT;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:27 EDTACTActavis' Dalvance shows positive Phase 3 results for skin infections
Actavis announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of Dalvance with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus. Preliminary top-line data demonstrated the 1500 mg single-dose of Dalvance achieved its primary endpoint of non-inferiority to the two-dose regimen at 48-72 hours after initiation of therapy. Actavis plans to file a supplemental New Drug Application with these data in Q3.
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.
07:09 EDTACTCipher Pharmaceuticals announces Markman hearing in Absorica patent suit
Subscribe for More Information
April 23, 2015
08:16 EDTACTActavis launches Avycaz anti-infective in U.S.
Subscribe for More Information
April 22, 2015
07:37 EDTACTOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 20, 2015
16:22 EDTACTActavis reports CCO Charles Mayr to retire for health reasons
Subscribe for More Information
08:12 EDTACTActavis's BOTOX label approved by FDA for spasticity treatment
Subscribe for More Information
07:18 EDTACTAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 14, 2015
06:18 EDTACTActavis urges U.S. appeals court to reverse decision on Namenda, AP reports
Subscribe for More Information
April 13, 2015
16:37 EDTACTActavis announces availability of 52mg Liletta to prevent pregnancy
Actavis and Medicines360, a nonprofit women's health pharmaceutical company, announced that Liletta 52 mg is now available in the U.S. for use by women to prevent pregnancy for up to three years.
10:52 EDTACTMeister says Actavis bought great companies, can continue growing
Subscribe for More Information
09:27 EDTACTActavis and Medicine360 announce Liletta es available in the U.S.
Subscribe for More Information
08:34 EDTACTZoetis names Actavis Executive Chairman Paul Bisaro to board
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use